de Morgan Stanley Catalyst Pharmaceutical CPRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 86.8 M | Comprar |
2,760,358
+73,059
| +3% | +USD 2.16 M | ﹤0.01% | 1690 |
|
|
2026
Q1 | USD 66.5 M | Vender |
2,687,299
-246,100
| -8% | -USD 5.86 M | ﹤0.01% | 1821 |
|
|
2025
Q4 | USD 68.5 M | Comprar |
2,933,399
+1,089,775
| +59% | +USD 24.3 M | ﹤0.01% | 1777 |
|
|
2025
Q3 | USD 36.3 M | Vender |
1,843,624
-1,339,899
| -42% | -USD 27.6 M | ﹤0.01% | 2302 |
|
|
2025
Q2 | USD 69.1 M | Comprar |
3,183,523
+788,968
| +33% | +USD 18.6 M | ﹤0.01% | 1630 |
|
|
2025
Q1 | USD 58.1 M | Comprar |
2,394,555
+306,505
| +15% | +USD 6.9 M | ﹤0.01% | 1687 |
|
|
2024
Q4 | USD 43.6 M | Comprar |
2,088,050
+264,776
| +15% | +USD 5.69 M | ﹤0.01% | 1958 |
|
|
2024
Q3 | USD 36.2 M | Comprar |
1,823,274
+810,595
| +80% | +USD 15 M | ﹤0.01% | 2172 |
|
|
2024
Q2 | USD 15.7 M | Vender |
1,012,679
-786,177
| -44% | -USD 12.2 M | ﹤0.01% | 2926 |
|
|
2024
Q1 | USD 28.7 M | Vender |
1,798,856
-162,683
| -8% | -USD 2.45 M | ﹤0.01% | 2296 |
|
|
2023
Q4 | USD 33 M | Comprar |
1,961,539
+1,048,444
| +115% | +USD 14.3 M | ﹤0.01% | 2154 |
|
|
2023
Q3 | USD 10.7 M | Comprar |
913,095
+19,027
| +2% | +USD 255 k | ﹤0.01% | 3077 |
|
|
2023
Q2 | USD 12 M | Vender |
894,068
-534,245
| -37% | -USD 7.69 M | ﹤0.01% | 2995 |
|
|
2023
Q1 | USD 23.7 M | Vender |
1,428,313
-309,090
| -18% | -USD 5.1 M | ﹤0.01% | 2236 |
|
|
2022
Q4 | USD 32.3 M | Comprar |
1,737,403
+173,258
| +11% | +USD 2.67 M | ﹤0.01% | 1894 |
|
|
2022
Q3 | USD 20.1 M | Comprar |
1,564,145
+112,883
| +8% | +USD 1.34 M | ﹤0.01% | 2186 |
|
|
2022
Q2 | USD 10.2 M | Comprar |
1,451,262
+209,936
| +17% | +USD 1.54 M | ﹤0.01% | 3048 |
|
|
2022
Q1 | USD 10.3 M | Comprar |
1,241,326
+976,218
| +368% | +USD 6.9 M | ﹤0.01% | 2882 |
|
|
2021
Q4 | USD 1.79 M | Comprar |
265,108
+43,508
| +20% | +USD 286 k | ﹤0.01% | 4663 |
|
|
2021
Q3 | USD 1.18 M | Vender |
221,600
-123,817
| -36% | -USD 677 k | ﹤0.01% | 4950 |
|
|
2021
Q2 | USD 1.98 M | Comprar |
345,417
+253,903
| +277% | +USD 1.31 M | ﹤0.01% | 4644 |
|
|
2021
Q1 | USD 422 k | Vender |
91,514
-74,661
| -45% | -USD 297 k | ﹤0.01% | 5246 |
|
|
2020
Q4 | USD 555 k | Vender |
166,175
-2,613,902
| -94% | -USD 8.78 M | ﹤0.01% | 5016 |
|
|
2020
Q3 | USD 8.26 M | Vender |
2,780,077
-39,958
| -1% | -USD 156 k | ﹤0.01% | 2203 |
|
|
2020
Q2 | USD 13 M | Comprar |
2,820,035
+107,406
| +4% | +USD 483 k | ﹤0.01% | 1741 |
|
|
2020
Q1 | USD 10.4 M | Vender |
2,712,629
-150,696
| -5% | -USD 619 k | ﹤0.01% | 1730 |
|
|
2019
Q4 | USD 10.7 M | Comprar |
2,863,325
+222,356
| +8% | +USD 1.04 M | ﹤0.01% | 2366 |
|
|
2019
Q3 | USD 14 M | Comprar |
2,640,969
+118,668
| +5% | +USD 632 k | ﹤0.01% | 1794 |
|
|
2019
Q2 | USD 9.7 M | Comprar |
2,522,301
+210,511
| +9% | +USD 909 k | ﹤0.01% | 2198 |
|
|
2019
Q1 | USD 11.8 M | Vender |
2,311,790
-937,883
| -29% | -USD 2.76 M | ﹤0.01% | 1869 |
|
|
2018
Q4 | USD 6.24 M | Comprar |
3,249,673
+1,502,771
| +86% | +USD 4.3 M | ﹤0.01% | 2630 |
|
|
2018
Q3 | USD 6.6 M | Comprar |
1,746,902
+4,428
| +0.3% | +USD 13.9 k | ﹤0.01% | 2881 |
|
|
2018
Q2 | USD 5.44 M | Comprar |
1,742,474
+557,090
| +47% | +USD 1.69 M | ﹤0.01% | 3055 |
|
|
2018
Q1 | USD 2.83 M | Comprar |
1,185,384
+334,250
| +39% | +USD 1.11 M | ﹤0.01% | 3654 |
|
|
2017
Q4 | USD 3.33 M | Comprar |
851,134
+486,096
| +133% | +USD 1.61 M | ﹤0.01% | 3529 |
|
|
2017
Q3 | USD 920 k | Comprar |
365,038
+266,264
| +270% | +USD 730 k | ﹤0.01% | 4487 |
|
|
2017
Q2 | USD 273 k | Comprar |
98,774
+72,429
| +275% | +USD 151 k | ﹤0.01% | 5158 |
|
|
2017
Q1 | USD 52 k | Comprar |
26,345
+13,926
| +112% | +USD 17.7 k | ﹤0.01% | 5816 |
|
|
2016
Q4 | USD 13 k | Comprar |
12,419
+10,212
| +463% | +USD 11.7 k | ﹤0.01% | 6098 |
|
|
2016
Q3 | USD 2 k | Vender |
2,207
-4,427
| -67% | -USD 3.99 k | ﹤0.01% | 6362 |
|
|
2016
Q2 | USD 5 k | Vender |
6,634
-806
| -11% | -USD 649 | ﹤0.01% | 6215 |
|
|
2016
Q1 | USD 9 k | Vender |
7,440
-18,297
| -71% | -USD 28.4 k | ﹤0.01% | 6156 |
|
|
2015
Q4 | USD 64 k | Vender |
25,737
-21,571
| -46% | -USD 61.8 k | ﹤0.01% | 5618 |
|
|
2015
Q3 | USD 142 k | Vender |
47,308
-323,205
| -87% | -USD 1.39 M | ﹤0.01% | 5253 |
|
|
2015
Q2 | USD 1.53 M | Vender |
370,513
-400,218
| -52% | -USD 1.6 M | ﹤0.01% | 3864 |
|
|
2015
Q1 | USD 3.34 M | Comprar |
770,731
+108,973
| +16% | +USD 393 k | ﹤0.01% | 3126 |
|
|
2014
Q4 | USD 1.96 M | Vender |
661,758
-574,421
| -46% | -USD 1.58 M | ﹤0.01% | 3581 |
|
|
2014
Q3 | USD 4.1 M | Comprar |
+1,236,179
| Nuevas | +USD 3.23 M | ﹤0.01% | 2799 |
|
|
2014
Q2 | – | Vender |
-3,161
| Cerradas | -USD 7 k | – | 6527 |
|
|
2014
Q1 | USD 7 k | Vender |
3,161
-5,540
| -64% | -USD 11.6 k | ﹤0.01% | 6185 |
|
|
2013
Q4 | USD 17 k | Comprar |
+8,701
| Nuevas | +USD 17.6 k | ﹤0.01% | 5907 |
|
Otros fondos que tienen CPRX en su cartera
Posición de Morgan Stanley en CPRX: resumen de T2 2026
Morgan Stanley aumentó su participación en Catalyst Pharmaceutical (CPRX) en 2.7% durante T2 2026, al comprar aproximadamente USD 2.16 M y elevar la posición a 2,760,358 acciones con un valor de USD 86.8 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1690.
Morgan Stanley reportó por primera vez una posición en CPRX en T4 2013 y la ha mantenido durante 50 trimestres desde entonces. Al cierre de T2 2026, 398 fondos que sigue Wall St. Rank mantienen una posición en CPRX.
- Al cierre de T2 2026, Morgan Stanley tenía 2,760,358 acciones de Catalyst Pharmaceutical con un valor de USD 86.8 M.
- Morgan Stanley compró 73,059 acciones de Catalyst Pharmaceutical en T2 2026, por un monto estimado de USD 2.16 M.
- Catalyst Pharmaceutical representó ﹤0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 1690.
- Morgan Stanley reportó por primera vez una posición en Catalyst Pharmaceutical en T4 2013 y la ha mantenido durante 50 trimestres desde entonces.
- Al cierre de T2 2026, 398 fondos que sigue Wall St. Rank tenían Catalyst Pharmaceutical en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.